Linagliptin Eg

Linagliptin, the active ingredient in Linagliptin Eg, is a dipeptidyl peptidase-4 (DPP-4) inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving glucose‑dependent insulin secretion. GNH USA supplies Linagliptin Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the management of disorders related to impaired glucose regulation, primarily type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycemic control by enhancing insulin secretion and reducing glucagon release in a glucose‑dependent manner. Adjunctive therapy with metformin or other oral agents: provides additional HbA1c reduction when monotherapy does not achieve target levels.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas that may be severe. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic enzyme elevation: abnormal liver function tests.

Linagliptin should be used with clinical vigilance in several situations. - Renal impairment: assess kidney function before initiating therapy. - Hepatic impairment: monitor liver enzymes periodically. - Hypersensitivity: discontinue immediately if an allergic reaction occurs. - Pregnancy and lactation: prescribe only if potential benefits outweigh risks. - Concomitant antidiabetic agents: adjust doses to avoid hypoglycaemia. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Linagliptin may interact with several drug classes. Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase linagliptin exposure. - Strong CYP3A4 inducers: may reduce linagliptin efficacy. Moderate Interactions (Monitor Closely): - Diuretics: may affect blood‑glucose control. - Insulin or sulfonylureas: increased risk of hypoglycaemia. - Rifampin: may lower plasma concentrations of linagliptin.